Purpose: To evaluate whether intravitreal functional plasminogen is elevated in eyes with branch retinal vein occlusion (BRVO) and to discover whether intravitreal plasminogen activities are correlated with the extent of blood-retina barrier (BRB) breakdown. Methods: Our study is a prospective case series of 20 consecutive patients with BRVO and 10 consecutive patients serving as controls. Vitreous taps were extracted from the central vitreous body and plasminogen was functionally determined in an innovative, ultrasensitive p-nitroanilide reaction after activation with streptokinase (100% of normal, %N = functional plasminogen in pooled normal citrated plasma). Intravitreal VEGF levels were assayed to estimate BRB breakdown. Results: Intravitreal functional plasminogen was detected in all analyzed samples (n = 30) and mean (±SD) plasminogen activities were found to be 0.97 ± 1.06%N (range: 0.03-3.9%N). Patients suffering from BRVO exhibited significantly higher intravitreal plasminogen (1.35 ± 1.11%N) in comparison with controls (0.20 ± 0.21%N, p < 0.001). Intravitreal VEGF concentrations in the BRVO group (576 ± 547 pg/ml) were significantly higher than these in controls (111 ± 120 pg/ml, p = 0.003). There was a significant correlation between intravitreal functional plasminogen and intravitreal VEGF levels (r = 0.519, p = 0.003). Conclusions: Intravitreal functional plasminogen is significantly elevated in eyes suffering from BRVO and correlates with the extent of BRB breakdown. The induction of posterior vitreous detachment by using intravitreally administered recombinant tissue plasminogen activator (enzymatic vitreolysis) should be explored in further investigations.

Keywords:
Branch retinal vein occlusion, Enzymatic vitreolysis, Fibrinolysis, Plasminogen, Tissue plasminogen activator, Vitreomacular adhesion, Vitreomacular traction
1.
McIntosh RL, Mohamed Q, Saw SM, Wong TY: Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:835-854.
2.
Avunduk AM, Cetinkaya K, Kapicioğlu Z, Kaya C: The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol Scand 1997;75:441-442.
3.
Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112.
4.
Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
5.
Bertelmann T, Kičová N, Messerschmidt-Roth A, Irle S, Sekundo W, Mennel S: The vitreomacular interface in retinal vein occlusion. Acta Ophthalmol 2011;89:e327-e331.
6.
Ascaso FJ, Padgett E, Núñez E, Villén L, Grzybowski A, Cristóbal JA: Branch retinal vein occlusion and vitreovascular traction: a preliminary spectral domain OCT case-control study. Graefes Arch Clin Exp Ophthalmol 2014;252:375-381.
7.
Charbonnel J, Glacet-Bernard A, Korobelnik JF, Nyouma-Moune E, Pournaras CJ, Colin J, Coscas G, Soubrane G: Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 2004;242:223-228.
8.
Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S: Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2004;138:907-914.
9.
Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA; MIVI-TRUST Study Group: Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;367:606-615.
10.
Hesse L, Nebeling B, Schroeder B, Heller G, Kroll P: Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res 2000;70:31-39.
11.
Bertelmann T, Mennel S, Sekundo W, Strodthoff S, Witteborn MC, Stief T, Nguyen N, Koss MJ: Intravitreal functional plasminogen is elevated in central retinal vein occlusion. Ophthalmic Res 2013;50:151-159.
12.
Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH: Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 2012;90:e98-e103.
13.
Hayreh SS: Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24:493-519.
14.
Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986;104:34-41.
15.
Shimada H, Akaza E, Yuzawa M, Kawashima M: Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2009;50:2953-2955.
16.
Scholl S, Kirchhof J, Augustin AJ: Pathophysiology of macular edema. Ophthalmologica 2010;224(suppl 1):8-15.
17.
Koss MJ, Naser H, Sener A, Ackermann H, Al-Sarireh F, Singh P, Koch FH: Combination therapy in diabetic macular oedema and retinal vein occlusion - past and present. Acta Ophthalmol 2012;90:580-589.
18.
Stief T: A functional plasminogen assay in clinical samples containing less than 1% of the normal plasma concentration. Hemost Lab 2013;6.
19.
Miyake K, Miyake T, Kayazawa F: Blood-aqueous barrier in eyes with retinal vein occlusion. Ophthalmology 1992;99:906-910.
20.
Murakami K, Trempe CL: Vitreous changes following central retinal vein occlusion (in Japanese). Nihon Ganka Gakkai Zasshi 1982;86:1201-1205.
21.
Kado M, Jalkh AE, Yoshida A, Takahashi M, Wazen N, Trempe CL, Schepens CL: Vitreous changes and macular edema in central retinal vein occlusion. Ophthalmic Surg 1990;21:544-549.
22.
Schepens CL, Avila MP, Jalkh AE, Trempe CL: Role of the vitreous in cystoid macular edema. Surv Ophthalmol 1984;28 (suppl):499-504.
23.
Hikichi T, Konno S, Trempe CL: Role of the vitreous in central retinal vein occlusion. Retina 1995;15:29-33.
24.
Takahashi MK, Hikichi T, Akiba J, Yoshida A, Trempe CL: Role of the vitreous and macular edema in branch retinal vein occlusion. Ophthalmic Surg Lasers 1997;28:294-299.
25.
Trempe CL, Takahashi M, Topilow HW: Vitreous changes in retinal branch vein occlusion. Ophthalmology 1981;88:681-687.
26.
Kado M, Trempe CL: Role of the vitreous in branch retinal vein occlusion. Am J Ophthalmol 1988;105:20-24.
27.
Murakami T, Takagi H, Kita M, Nishiwaki H, Miyamoto K, Ohashi H, Watanabe D, Yoshimura N: Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;142:318-320.
28.
Kumagai K, Ogino N, Furukawa M, Larson E: Three treatments for macular edema because of branch retinal vein occlusion: intravitreous bevacizumab or tissue plasminogen activator, and vitrectomy. Retina 2012;32:520-529.
29.
Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S: Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998;4:177-182.
30.
Heissig B, Ohki-Koizumi M, Tashiro Y, Gritli I, Sato-Kusubata K, Hattori K: New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis. Int J Hematol 2012;95:131-137.
31.
Stefansson S, McMahon GA, Petitclerc E, Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003;9:1545-1564.
32.
Hattenbach LO, Allers A, Gümbel HO, Scharrer I, Koch FH: Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy. Retina 1999;19:383-389.
33.
Parfenova EV, Plekhanova VV, Stepanova VV, Men'shikov MIU, Tsokaleva ZI, Talitskiĭ KA, Rakhmat-zade TM, Traktuev DO, Torosian NA, Rogunova NI, Ratner EI, Tkachuk VA: Plasminogen activator of urokinase-type: mechanisms of involvement in vessel remodeling and angiogenesis, gene therapy approaches to ischemia (in Russian). Ross Fiziol Zh Im I M Sechenova 2004;90:547-568.
34.
Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK: Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 2008;22:42-48.
35.
Mayr-Sponer U, Waldstein SM, Kundi M, Ritter M, Golbaz I, Heiling U, Papp A, Sima-der C, Schmidt-Erfurth U: Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology 2013;120:2620-2629.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.